Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients

Journal of Neuro-Oncology

Volumn 120, Issue 3, 2014, Pages 499-506

  Peters, Katherine B ^a   West, Miranda J ^a   Hornsby, Whitney E ^a   Waner, Emily ^a   Coan, April D ^b   McSherry, Frances ^a   Herndon, James E ^a   Friedman, Henry S ^a   Desjardins, Annick ^a   Jones, Lee W ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Fatigue; Quality of life; Recurrent glioma

Indexed keywords

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREDICTOR VARIABLE; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; TUMOR RECURRENCE; AGED; BRAIN NEOPLASMS; CANCER GRADING; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGY; SALVAGE THERAPY; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; FATIGUE; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SALVAGE THERAPY; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84911422614     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1574-3     Document Type: Article

References (45)

1. Ohgaki H (2009) Epidemiology of brain tumors. Methods Mol Biol 472:323–342. doi:10.1007/978-1-60327-492-0_14
2. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin oncol 17:2572–2578
3. Kyritsis AP, Levin VA (2011) An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 67:971–983. doi:10.1007/s00280-011-1617-9
4. Wen PY, Brandes AA (2009) Treatment of recurrent high-grade gliomas. Curr Opin Neurol 22:657–664. doi:10.1097/WCO.0b013e32833229e3
5. Heimans JJ, Taphoorn MJ (2002) Impact of brain tumour treatment on quality of life. J Neurol 249:955–960. doi:10.1007/s00415-002-0839-5
6. Taphoorn MJ, Sizoo EM, Bottomley A (2010) Review on quality of life issues in patients with primary brain tumors. Oncologist 15:618–626. doi:10.1634/theoncologist.2009-0291
7. Cheng JX, Liu BL, Zhang X, Lin W, Zhang YQ, Liu WP, Zhang JN, Lin H, Wang R, Yin H (2010) Health-related quality of life in glioma patients in China. BMC Cancer 10:305. doi:10.1186/1471-2407-10-305
8. Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, Wong R, de Witte O, Cairncross JG, Efficace F, Mirimanoff RO, Forsyth P, van den Bent MJ, Weller M, Bottomley A (2007) The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer 97:302–307. doi:10.1038/sj.bjc.6603876
9. Brown PD, Maurer MJ, Rummans TA, Pollock BE, Ballman KV, Sloan JA, Boeve BF, Arusell RM, Clark MM, Buckner JC (2005) A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 57:495–504 discussion 495-504 12
10. Giovagnoli AR, Silvani A, Colombo E, Boiardi A (2005) Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry 76:562–568. doi:10.1136/jnnp.2004.036186
11. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865–871. doi:10.1016/S1470-2045(09)70200-1
12. Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, Brandes AA, van der Rijt CC, Bernsen HJ, Frenay M, Tijssen CC, Lacombe D, van den Bent MJ (2007) Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol 25:5731–5737. doi:10.1200/JCO.2007.11.1476
13. Brown PD, Ballman KV, Rummans TA, Maurer MJ, Sloan JA, Boeve BF, Gupta L, Tang-Wai DF, Arusell RM, Clark MM, Buckner JC (2006) Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol 76:283–291. doi:10.1007/s11060-005-7020-9
14. Meyers CA, Hess KR, Yung WK, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18:646–650
15. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. doi:10.1200/JCO.2009.26.3541
16. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151–1161
17. Van Belle S, Paridaens R, Evers G, Kerger J, Bron D, Foubert J, Ponnet G, Vander Steichel D, Heremans C, Rosillon D (2005) Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue. Support Care Cancer 13(4):246–254. doi:10.1007/s00520-004-0734-y
18. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25:43–46
19. Cella D, Lai JS, Chang CH, Peterman A, Slavin M (2002) Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94:528–538. doi:10.1002/cncr.10245
20. Ruden E, Reardon DA, Coan AD, Herndon JE 2nd, Hornsby WE, West M, Fels DR, Desjardins A, Vredenburgh JJ, Waner E, Friedman AH, Friedman HS, Peters KB, Jones LW (2011) Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol 29:2918–2923. doi:10.1200/JCO.2011.34.9852
21. Montazeri A (2009) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7:102. doi:10.1186/1477-7525-7-102
22. Bland JM, Altman DG (1995) Multiple significance tests: the Bonferroni method. BMJ 310:170
23. Sullivan PW, Nelson JB, Mulani PM, Sleep D (2006) Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res 15:1297–1306. doi:10.1007/s11136-006-0003-2
24. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT (2007) Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat 105:209–219. doi:10.1007/s10549-006-9447-x
25. Brown DJ, McMillan DC, Milroy R (2005) The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 103:377–382. doi:10.1002/cncr.20777
26. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(353–360):14
27. Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C (2000) NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology 14:151–161
28. Wagner LI, Cella D (2004) Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 91:822–828. doi:10.1038/sj.bjc.6602012
29. Piper BF, Cella D (2010) Cancer-related fatigue: definitions and clinical subtypes. J Natl Compr Cancer Netw: JNCCN 8:958–966
30. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O’Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI (2010) Cancer-related fatigue. J Natl Compr Cancer Netw: JNCCN 8:904–931
31. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W (1998) Progress toward guidelines for the management of fatigue. Oncology 12:369–377
32. Brown LF, Kroenke K (2009) Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 50:440–447. doi:10.1176/appi.psy.50.5.440
33. Morton A, King D (2003) Fatigue and endocrine disorders: causes and comorbidities. Aust Fam Physician 32:895–900
34. Duffner PK (2004) Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 10:293–310. doi:10.1097/01.nrl.0000144287.35993.96
35. Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, Rubin P (1993) Hypothalamic-pituitary dysfunction after radiation for brain tumors. New Engl J Med 328:87–94. doi:10.1056/NEJM199301143280203
36. Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, Jacobsen PB, Syrjala KL, Von Roenn JH, Cella D (2008) Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Cancer Netw: JNCCN 6:448–455
37. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY (2007) Medical management of brain tumor patients. Neurol Clin 25:1035–1071. doi:10.1016/j.ncl.2007.07.015
38. Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, Slotman BJ, Klein M (2011) Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 29:4430–4435. doi:10.1200/JCO.2011.35.5750
39. Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH (2010) Risk factors for fatigue severity in primary brain tumor patients. Cancer 116:2707–2715. doi:10.1002/cncr.25018
40. Pruitt AA (2011) Medical management of patients with brain tumors. Curr Treat Options Neurol 13:413–426. doi:10.1007/s11940-011-0132-y
41. Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, Wefel JS (2011) A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol. doi:10.1007/s11060-011-0723-1
42. Meyers CA, Weitzner MA, Valentine AD, Levin VA (1998) Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16:2522–2527
43. Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, Lesser G, McMullen K, McQuellon R, Naughton M, Rapp S, Stieber V, Shaw EG (2007) A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 69:1496–1501. doi:10.1016/j.ijrobp.2007.05.076
44. Jones LW, Liang Y, Pituskin EN, Battaglini CL, Scott JM, Hornsby WE, Haykowsky M (2011) Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. Oncologist 16:112–120. doi:10.1634/theoncologist.2010-0197
45. Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305–1309. doi:10.1200/JCO.2005.04.6086